RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/25363635 below:

Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

doi: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2. Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

Affiliations

¹ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members).
² Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
³ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
⁴ New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Pathology, University of Virginia, Charlottesville, Virginia.
⁵ New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Global Cancer Initiative, Chestertown, Maryland.
⁶ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), University of New Mexico Health Sciences Center, Albuquerque, New Mexico. cwheeler@salud.unm.edu.

PMID: 25363635
PMCID: PMC4294978
DOI: 10.1158/1055-9965.EPI-14-0775

Item in Clipboard

Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer

Nancy E Joste et al. Cancer Epidemiol Biomarkers Prev. 2015 Jan.

doi: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2. Affiliations

¹ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members).
² Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
³ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
⁴ New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Pathology, University of Virginia, Charlottesville, Virginia.
⁵ New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Global Cancer Initiative, Chestertown, Maryland.
⁶ Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico. New Mexico HPV Pap Registry Steering Committee (see acknowledgements for the list of collaborative members). Department of Obstetrics and Gynecology, House of Prevention Epidemiology (HOPE), University of New Mexico Health Sciences Center, Albuquerque, New Mexico. cwheeler@salud.unm.edu.

PMID: 25363635
PMCID: PMC4294978
DOI: 10.1158/1055-9965.EPI-14-0775

Item in Clipboard

Abstract

Background: The New Mexico HPV Pap Registry was established to measure the impact of cervical cancer prevention strategies in the United States. Before widespread human papillomavirus (HPV) vaccine implementation, we established the baseline prevalence for a broad spectrum of HPV genotypes across the continuum of cervical intraepithelial neoplasia (CIN) and cancer.

Methods: A population-based sample of 6,272 tissue specimens was tested for 37 HPV genotypes. The number of specimens tested within each diagnostic category was: 541 negative, 1,411 CIN grade 1 (CIN1), 2,226 CIN grade 2 (CIN2), and 2,094 CIN grade 3 (CIN3) or greater. Age-specific HPV prevalence was estimated within categories for HPV genotypes targeted by HPV vaccines.

Results: The combined prevalence of HPV genotypes included in the quadrivalent and nonavalent vaccines increased from 15.3% and 29.3% in CIN1 to 58.4% and 83.7% in CIN3, respectively. Prevalence of HPV types included in both vaccines tended to decrease with increasing age for CIN1, CIN2, CIN3, and squamous cell carcinoma (SCC), most notably for CIN3 and SCC. The six most common HPV types in descending order of prevalence were HPV-16, -31, -52, -58, -33, and -39 for CIN3 and HPV-16, -18, -31, -45, -52, and -33 for invasive cancers.

Conclusions: Health economic modeling of HPV vaccine impact should consider age-specific differences in HPV prevalence.

Impact: Population-based HPV prevalence in CIN is not well described, but is requisite for longitudinal assessment of vaccine impact and to understand the effectiveness and performance of various cervical screening strategies in vaccinated and unvaccinated women.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: All other authors report no conflicts of interest.

Figures
Figure 1. Age-group trends in the HPV…

Figure 1. Age-group trends in the HPV type attribution for HPV16 and HPV18 (bivalent), HPV6,…
Figure 1. Age-group trends in the HPV type attribution for HPV16 and HPV18 (bivalent), HPV6, 11, 16, and 18 (quadrivalent), and HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 (nonavalent) in CIN1 (A), CIN2 (B), and CIN3 (C)

Tests for age trend are shown below. CIN1: bivalent p = 0.1086; quadrivalent, p = 0.0232; nonavalent, p = 0.0003; carcinogenic, p < 0.0001; any HPV, p < 0.0001; CIN2: bivalent, p = 0.0053; quadrivalent, p = 0.0047; nonavalent, p = 0.0212; carcinogenic, p = 0.0005; any HPV, p = 0.0015; CIN3: bivalent, p < 0.0001; quadrivalent, p < 0.0001; nonavalent, p = 0.0003; carcinogenic, p = 0.0091; any HPV, p = 0.1308